A 2-Cohort Study to Evaluate the Absolute Bioavailability, Absorption, Distribution, Metabolism and Excretion of TD-1473 Following an Intravenous and an Oral Dose of [14C]-TD-1473 in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 20 Apr 2018
At a glance
- Drugs TD 1473 (Primary) ; TD 1473 (Primary)
- Indications Gastrointestinal disorders; Inflammatory bowel diseases; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Theravance Biopharma
- 13 Apr 2018 Status changed from recruiting to completed.
- 30 Jan 2018 Planned initiation date changed to 31 Jan 2018.
- 29 Jan 2018 New trial record